ReviewThe Journal of allergy and clinical immunology2017
Promising approaches for the treatment and prevention of viral respiratory illnesses.
Review in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Vaccines for the common cold.The Cochrane database of systematic reviews · 2022Pooled it
- Evaluation of the FPMC respiratory panel for detection of respiratory tract pathogens in nasopharyngeal swab and sputum specimens.Virology journal · 2024Article
- Respiratory eukaryotic virome expansion and bacteriophage deficiency characterize childhood asthma.Scientific reports · 2023Article
- Quinones as Promising Compounds against Respiratory Viruses: A Review.Molecules (Basel, Switzerland) · 2023Review
- Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.Pharmaceutics · 2022Review
- Boosting nitric oxide in stress and respiratory infection: Potential relevance for asthma and COVID-19.Brain, behavior, & immunity - health · 2021Review
- Article
- Seaweed Sulfated Polysaccharides against Respiratory Viral Infections.Pharmaceutics · 2021Review
- A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.Journal of biomolecular structure & dynamics · 2021Review
- Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response.Scientific reports · 2021Article
- Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.American journal of cardiovascular disease · 2021Review
- Lower respiratory tract infection in the community: associations between viral aetiology and illness course.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Article
- How can nanotechnology help to combat COVID-19? Opportunities and urgent need.Journal of nanobiotechnology · 2020Review
- Rhinovirus C Is Associated With Severe Wheezing and Febrile Respiratory Illness in Young Children.The Pediatric infectious disease journal · 2020Observational
- MicroRNAs in Asthma and Respiratory Infections: Identifying Common Pathways.Allergy, asthma & immunology research · 2020Review
- Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Community-acquired Respiratory Viruses Are a Risk Factor for Chronic Lung Allograft Dysfunction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Nanoparticle-Based Vaccines Against Respiratory Viruses.Frontiers in immunology · 2019Review
- Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments.Allergy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral respiratory tract infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of viral species and subtypes have been associated with these conditions, with influenza viruses, respiratory syncytial virus, and rhinoviruses being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory tract infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission, or even just the symptoms. Strategies targeting all these aspects are developing concurrently, and several novel and promising approaches are emerging. In this perspective we overview the entire range of options and highlight some of the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, and vaccines and public health policies toward prevention. Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.